Introduction {#Sec1}
============

As the novel coronavirus disease (COVID-19) pandemic evolves, several patients dependent on mechanical ventilation have required tracheostomy. Approximately 3.2% of all confirmed COVID-19 cases in China required invasive mechanical ventilation \[[@CR1]\], and 17% of hospitalized patients in one series required intubation \[[@CR2]\]. Tracheostomy is an aerosol generating procedure (AGP) similar to endotracheal intubation, extubation, bronchoscopy, manual bag-mask ventilation, administration of nebulized medications, cardiopulmonary resuscitation, noninvasive positive pressure ventilation (NIPPV) and heated high flow nasal cannula (HHFNC). The SARS-CoV-2 virus is highly transmissible, and infection of healthcare workers has been widely documented, particularly with performance of AGPs \[[@CR3], [@CR4]\]. In one systematic review, healthcare providers caring for severe acute respiratory syndrome (SARS) patients during the 2002--2004 epidemic who performed tracheostomy were four times more likely to contract the disease compared with those who did not \[[@CR5]\]. Recent guidelines on performance of tracheostomy on patients with COVID-19 recommend these procedures be performed in negative-pressure rooms (NPR) \[[@CR6], [@CR7]\]; however, the availability of NPRs is typically limited in regions with high case load or limited resources.

Multiple innovative devices designed to decrease the risk of disease transmission during AGPs performed on COVID-19 patients have been reported \[[@CR8]--[@CR19]\]. The majority of these devices are boxes, drapes or tents that surround the patient's head to contain aerosols \[[@CR12], [@CR15]--[@CR19]\], while some devices attempt to generate negative pressure to promote clearance of aerosols from the procedural space \[[@CR8]--[@CR11], [@CR13], [@CR14]\]. More recent studies have called into question the role of these devices in the care of COVID-19 patients \[[@CR20]--[@CR22]\]. Containment boxes, tents and drapes without a negative-pressure system do not decrease---and may even increase---the concentration of SARS-CoV-2 virus-sized particles around the proceduralist \[[@CR20]\]. There are also concerns that these devices will increase procedural complexity and failure rates \[[@CR21], [@CR22]\]. It is critical therefore that any new device is validated in its ability to minimize the concentration of SARS-CoV-2 virus-sized particles adjacent to the proceduralist, and that the feasibility of performing the procedure in question under real-world conditions on patients be demonstrated. The latter criterion may be especially important for tracheostomy, which is a sterile procedure that is more complex and requires more procedural space than intubation, particularly if performed with bronchoscopy. Devices that generate negative pressure must demonstrate an air-exchange rate that meets the standards of the Centers for Disease Control and Prevention (CDC) for NPRs \[[@CR23]\].

Objective {#Sec2}
=========

To demonstrate the feasibility of percutaneous dilatational tracheostomy (PDT) performed using a novel low-cost negative-pressure tent (AerosolVE).

Setting {#Sec3}
-------

Intensive care units providing care for COVID-19 patients.

Participants {#Sec4}
------------

Intubated adult patients with COVID-19 requiring tracheostomy in April and May 2020.

Design {#Sec5}
------

The institutional review board (IRB) reviewed the study and waived the need for approval. This is a retrospective review of consecutive PDT procedures performed using the AerosolVE tent on patients with COVID-19. Clinical use of the tent during the pandemic was under an institutional innovative clinical care protocol. Informed consent was obtained from legally authorized representatives for use of the tent, as well as acquisition of photographic images and video.

The AerosolVE tent was developed at the Michigan Center for Integrative Research in Critical Care, University of Michigan, Ann Arbor, MI, in collaboration with FlexSys Inc, Ann Arbor, MI. The tent consists of a clear plastic canopy with multiple slits that allow access to the patient, supported by a foldable frame. The tent is attached to a portable U-shaped base and can be folded back onto the base (Fig. [1](#Fig1){ref-type="fig"}). Air within the tent is drawn out through a high-efficiency particulate air (HEPA) filter via negative pressure generated by a vacuum motor. Air within the tent is exchanged over 600 times/h, 50 times the 12 air cycles/h recommended by the CDC \[[@CR23]\]. While the clear plastic canopy and HEPA filter are disposable following a procedure, the base may be reused for the same patient or other patients following disinfection with anti-viral wipes appropriate for SARS-CoV-2.Fig. 1Diagrammatic representation of the AerosolVE negative-pressure tent

### Preliminary Data {#Sec6}

Initial testing was previously performed with healthy volunteers and a particle generator (TSI Inc, Shoreview, MN, USA) to simulate aerosol generation by a COVID-19 patient \[[@CR24]\]. A condensation particle counter (Model 3007, TSI Inc, Shoreview, MN, USA) was used, which detects particles 0.01 μm to \> 1 μm (the SARS-CoV-2 virus is 0.06--0.14 μm). The particle content of ambient room air was 100--300 particles/cm^3^. The use of HHFNC 60 L/min combined with use of the particle generator generated a mean air particle content (mAPC) inside the tent of 18,867/cm^3^, while the particle count outside was 139/cm^3^. Addition of a nebulizer mask with saline solution at 10 L/min to HHFNC 60 L/min, without the particle generator, generated a mAPC inside the tent of 66,835/cm^3^, while the count was 338/cm^3^ outside. The use of continuous positive airway pressure (CPAP) in association with the particle generator resulted in a mAPC inside the tent of 27,802/cm^3^, and 179/cm^3^ outside.

### Performance of Tracheostomy {#Sec7}

Indications for and timing of tracheostomy were at the discretion of the primary clinical team. The proceduralists were intensivists with 15 and 5 years' experience performing percutaneous dilatational tracheostomy (PDT). All individuals within the room used appropriate personal protective equipment (PPE), including powered air purifying respirator (PAPR) hoods or N95 masks with face shields. Our technique of PDT using real-time ultrasound guidance has been previously described \[[@CR25]\]. The Cook Ciaglia Blue Rhino® (Cook Medical Inc., Bloomington, IN) single-stage dilator PDT kit was used. A Dräger Evita V500 ventilator (Dräger Inc., Lübeck, Germany) was used during the procedures. Patients were deeply sedated with a propofol infusion, pre-treated with fentanyl, and then paralyzed with rocuronium. The tent was first positioned around the patient with the canopy folded back. The skin over the anterior neck was prepared with chlorhexidine, followed by application of sterile drapes and setup of equipment on the sterile field. The canopy was then drawn into position over the sterile field. The proceduralist's arms were introduced through slits in the side of the tent, which were held open by an assistant during hand passage to minimize the risk of contamination of sterile gloves. Bronchoscopy was performed as required by a proceduralist at the head of the bed, through additional slits in the canopy. In accordance with institutional guidelines, the ventilator was placed on standby mode for all anticipated disconnections and disruptions of the closed circuit during the procedure. The endotracheal tube was withdrawn under real-time ultrasound guidance for the first two patients \[[@CR25]\], and under bronchoscopic guidance for the third patient. The remaining steps of PDT were then completed, including local anesthetic, tracheal puncture, passage of the guidewire, confirmation of guidewire position, incision, blunt dissection, dilatation of the stoma, and delivery of the tracheostomy tube \[[@CR25]\]. (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}) Following completion of the procedure, bronchoscopy was performed to confirm good position of the tracheostomy tube. The bronchoscope was also introduced through the tracheostomy tube to confirm good position relative to the carina and perform pulmonary toilet. The tracheostomy tube was secured in place and the tent removed.Fig. 2Performance of tracheostomy within the AerosolVE tent---Case 3Fig. 3Bronchoscopy and tracheostomy performed within the AerosolVE tent---Case 2

Main Outcomes and Measures {#Sec8}
--------------------------

The outcome of interest was successful completion of real-time ultrasound-guided PDT and bronchoscopy within the AerosolVE tent, without complications and without transmission of infection to healthcare staff. Potential complications related to the procedure included, but were not limited to, loss of airway during procedure, cardiac arrest during the procedure, bleeding requiring intervention, stomal or mediastinal infection, posterior wall injury, pneumothorax, pneumomediastinum, nerve injury, sustained hypoxia (SpO~2~ \< 90% for \> 1 min) during the procedure, false passage of tube, inability to complete procedure, conversion to surgical tracheostomy, need for revision of tracheostomy, tracheal granuloma, and early dislodgement (within 7 days).

Results {#Sec9}
=======

Three patients underwent PDT with use of the AerosolVE tent. The first patient was a 53-year-old man with a history of hypertension, with COVID-19-related acute respiratory distress syndrome (ARDS), prolonged unresponsiveness, and multiple bilateral borderzone ischemic strokes intubated 21 days prior to tracheostomy. He was weaned to a FiO~2~ of 40% and positive end-expiratory pressure (PEEP) of 8 cmH2O, but failed multiple spontaneous breathing trials (SBT) and was insufficiently responsive to reliably protect his airway. He also remained unresponsive to pain when weaned off all sedation. The second patient was a 53-year-old woman with a history of hypertension, diabetes, coronary artery disease, mitral valve replacement, and COVID-19 who in addition to ARDS also suffered cerebellar hemorrhage, hydrocephalus, and acute severe myopathy. She was intubated 26 days prior to tracheostomy. This patient had been weaned to FiO~2~ 40% and PEEP 10 cmH2O but also failed multiple SBTs and was unable to protect her airway. The third patient was a 69-year-old morbidly obese man with diabetes, hypertension, and coronary artery disease intubated 21 days prior to tracheostomy for COVID-19 associated ARDS. He was on FiO~2~ 50% and PEEP 12 cm H~2~O and could not be weaned further.

Following initial setup, withdrawal of the endotracheal tube was completed in \< 5 min and the remainder of the procedure under 10 min. Post-procedure bronchoscopy required \< 10 min. Transient hypoxemia (SpO~2~ \< 90%) for \< 1 min was observed in the first 2 cases, both times in conjunction with placing the ventilator on standby mode for anticipated disconnections. No sustained hypoxemia or other complications were subsequently observed, and none of the healthcare staff present in the room for either procedure demonstrated signs of infection at the time of this report 4 weeks later.

Discussion {#Sec10}
==========

In this case series, we have demonstrated the feasibility of use of a novel negative-pressure tent during bedside tracheostomy for ventilator-dependent patients with COVID-19. This is the first documented report of PDT performed on COVID-19 patients using a negative-pressure device validated to decrease SARS-CoV-2 virus-sized aerosol, with an air-exchange rate that exceeds the CDC recommended rate. The device may therefore increase the safety of physicians, nurses, and respiratory therapists involved in these procedures. While use during tracheostomy may represent the most complex application of this device, the device has also been used at our institution for other AGPs such as endotracheal intubation and NIPPV. The device may be particularly valuable when NPRs are unavailable. The device uses low-cost materials and is a significantly cheaper alternative to conversion of existing rooms to NPRs \[[@CR26]\]. The portability of the device permits use in varied settings, including the emergency department, intensive care units, operating rooms, other procedural areas, and general care units.

Decreasing risk to healthcare staff during AGPs has implications beyond direct benefit to staff involved. The availability of this device may facilitate tracheostomy performed within a more typical timeframe (7--10 days), without the need for repeated testing or waiting for a more prolonged duration as recommended by some guidelines \[[@CR6], [@CR7]\]. Earlier tracheostomy---when clinically appropriate---may improve patient comfort, permit earlier weaning of sedation, and possibly facilitate earlier liberation from the ICU \[[@CR27]\]. Of note, the only periods of transient oxygen desaturation during the procedures were during periods of planned discontinuation of mechanical ventilation (standby mode) prior to anticipated circuit breaks to decrease aerosolization, as recommended by current guidelines \[[@CR6], [@CR7]\]. The very high air-exchange rate within the tent may make such disconnections unnecessary, and thereby increase the safety of the procedure for COVID-19 patients who typically have limited pulmonary reserve and suffer oxygen desaturation with even brief discontinuation of mechanical ventilation.

Several other devices designed to decrease transmission risk during AGPs have been reported during the pandemic, in both the medical literature \[[@CR8]--[@CR16]\] and the lay press \[[@CR17]--[@CR19]\]. The majority of these box, drape, and tent devices do not generate negative pressure in the procedural space. A recent study that utilized a particle counter during simulated AGPs has demonstrated that such devices do not decrease---and may actually increase---the aerosol exposure of operators \[[@CR20]\]. Another study has demonstrated that these devices increase failure rates and procedural time during endotracheal intubation \[[@CR21], [@CR22]\]. Prior to routine clinical use on COVID-19 patients, devices designed to decrease disease transmission via aerosol must therefore be validated in two ways: 1) the ability of the device to greatly decrease the concentration virus-sized (0.06--0.14 μm) particles in the proximity of the operator and 2) the feasibility of performing the specific procedure in question within the device in the challenging real-world conditions that exist when providing care to COVID-19 patients. Reports from Foster et al. \[[@CR10]\] and Bertroche et al. \[[@CR8]\] describe custom setups to generate a negative-pressure field over the procedural space during tracheostomy, used on one patient each at the time of the reports. While innovative, these custom-made constructions have not yet been validated with particle counters, and the air-exchange rate has not been reported. Also the need to assemble a field with individual components for each procedure may increase setup time compared to a prefabricated device. Fox et al. have described a negative-pressure tent with an air exchange rate of approximately 22/h; however, this is substantially lower than the 600 exchanges/h documented with AerosolVE \[[@CR11]\]. Also this tent may not be tailored to sterile procedures, and clinical use of this device has not yet been reported \[[@CR11]\]. Convissar and colleagues have described the use of a negative-pressure system for AGPs in the operating room that utilizes a Stryker Neptune™ (Stryker Corporation, Kalamazoo, MI) high-power suction system \[[@CR9]\]. However, this system is relatively small and has not yet demonstrated feasibility of use with tracheostomy. Adverse events have occurred when the Stryker™ system, which is compatible with a variety of tubing used in routine clinical care, was inadvertently connected to chest tubes \[[@CR9]\].

This case-series only demonstrates feasibility. Larger studies are necessary to optimally demonstrate the safety and efficacy of this device. The most significant limitation observed was the risk of glove contamination within the tent, and the relatively confined procedural space, although neither proceduralist reported such contamination during the 3 cases in this report. The consequences of inadvertent contamination may be lower in procedures performed on a non-sterile region such as the airway. A newer version of the tent is larger and provides greater procedural space in addition to a higher air-flow rate. It should also be noted that tracheostomy is an elective procedure that allows time to position and setup a negative-pressure device. Emergency AGPs such as endotracheal intubation performed with any negative-pressure device should likely be simulated on mannequins before they are performed on COVID-19 patients.

We conclude that it is feasible to perform bedside tracheostomy on COVID-19 patients while using the AerosolVE negative-pressure tent. This is a promising low-cost device to decrease risk to healthcare providers during AGPs.
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